Tissue transglutaminase induces Epithelial-Mesenchymal-Transition and the acquisition of stem cell like characteristics in colorectal cancer cells

Oncotarget

Volumn 8, Issue 12, 2017, Pages 20025-20041

  Ayinde, Oluseyi ^a   Wang, Zhuo ^a   Griffin, Martin ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Cancer stem cells; Colorectal cancer; Epithelial Mesenchymal Transition; Tissue transglutaminase

Indexed keywords

BETA CATENIN; HERMES ANTIGEN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCCLUDIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN; WNT PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TGFB1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UPREGULATION; APOPTOSIS; CELL PROLIFERATION; COLORECTAL TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WNT SIGNALING;

APOPTOSIS; BETA CATENIN; BIOMARKERS, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; TRANSFORMING GROWTH FACTOR BETA1; TRANSGLUTAMINASES; TUMOR CELLS, CULTURED; WNT SIGNALING PATHWAY;

EID: 85015745425     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15370     Document Type: Article

References (55)

1. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nature Review Molecular Cell Biology. 2014; 15:178-196.
2. Liu X, Zhang Z, Sun L, Chai N, Tang S, Jin J, Hu H, Nie Y, Wang X, Wu K, Jin H, Fan D. microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis. 2011; 32:1798-1805.
3. Leng Z, Tao K, Xia Q, Tan J, Yue Z, Chen J, Xi H, Li J, Zheng H. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. Plos One. 2013; 8:e56082.
4. Zhang Z, Liu X, Feng B, Liu N, Wu Q, Han Y, Nie Y, Wu K, Shi Y, Fan D. STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene. 2015; 34:4808-20.
5. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM. Overexpression of Snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Medicine. 2012; 1:5-16.
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
7. Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochemical Journal. 2002; 368:377-396.
8. Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K. Transglutaminase Regulation of Cell Function. Physiological Reviews. 2014; 94:383-417.
9. Wang Z, Griffin M. TG2, a novel extracellular protein with multiple functions. Amino Acids. 2012; 42:939-949.
10. Agnihotri N, Kumar S, Mehta K. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Research. 2013; 15:202.
11. Wang Z, Griffin M. The role of TG2 in regulating S100A4-mediated mammary tumour cell migration. Plos One. 2013; 8:e57017.
12. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, et al. Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma. Cancer Research. 2008; 68:5849-5858.
13. Oh K, Ko E, Kim HS, Park AK, Moon HG, Noh DY, Lee DS. Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells. Breast Cancer Res. 2011;13:R96.
14. Verderio E, Gaudry C, Gross S, Smith C, Downes S, Griffin M. Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor-beta binding protein-1. The journal of histochemistry and cytochemistry. 1999; 47:1417-1432.
15. Kumar S, Mehta K. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids. 2013; 44:81-88.
16. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappa B in cancer cells: Delineation of a novel pathway. Cancer Res. 2006; 66:8788-8795.
17. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012; 31:2521-2534.
18. Torricelli P, Caraglia M, Abbruzzese A, Beninati S. gamma-Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins. Amino Acids. 2013; 44:45-51.
19. Kotsakis P, Wang Z, Collighan R, Griffin M. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26. Amino Acids. 2011; 41:909-921.
20. Fok JY, Mehta K. Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells. Apoptosis. 2007; 12:1455-1463.
21. Kotsakis P, Griffin M. Tissue transglutaminase in tumour progression: friend or foe? Amino Acids. 2007; 33:373-384.
22. Jones RA, Kotsakis P, Johnson TS, Chau DYS, Ali S, Melino G, Griffin M. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ. 2006; 13:1442-1453.
23. Hewitt RE, McMarlin A, Kleiner D, Wersto R, Martin P, Tsokos M, Stamp GW, Stetler-Stevenson WG. Validation of a model of colon cancer progression. The Journal of pathology. 2000; 192:446-454.
24. Badarau E, Wang Z, Rathbone DL, Costanzi A, Thibault T, Murdoch CE, El Alaoui S, Bartkeviciute M, Griffin M. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions. Chemistry & biology. 2015; 22:1347-1361.
25. Telci D, Collighan RJ, Basaga H, Griffin M. Increased TG2 Expression Can Result in Induction of Transforming Growth Factor beta 1, Causing Increased Synthesis and Deposition of Matrix Proteins, Which Can Be Regulated by Nitric Oxide. Journal of Biological Chemistry; 284:29547-29558.
26. Nyabam S, Wang Z, Thibault T, Oluseyi A, Basar R, Marshall L, Griffin M. A novel regulatory role for tissue transglutaminase in epithelial-mesenchymal transition in cystic fibrosis. Biochim Biophys Acta. 2016; 1863:2234-2244.
27. Volmer MW, Radacz Y, Hahn SA, Klein-Scory S, Stuhler K, Zapatka M, Schmiegel W, Meyer HE, Schwarte-Waldhoff I. Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a 'secretome' analysis. Proteomics. 2004; 4:1324-1334.
28. Chow JYC, Cabral JA, Chang J, Carethers JM. TGFβ modulates PTEN expression independently of SMAD signaling for growth proliferation in colon cancer cells. Cancer biology & therapy. 2008; 7:1694.
29. Leppa S, Saffrich R, Ansorge W, Bohmann D. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. Embo Journal. 1998; 17:4404-4413.
30. Clevers H, Nusse R. Wnt/β-Catenin Signaling and Disease. Cell. 2012; 149:1192-1205.
31. Miyoshi N, Ishii H, Mimori K, Tanaka F, Hitora T, Tei M, Sekimoto M, Doki Y, Mori M. TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer. Annals of Surgical Oncology. 2010; 17: 967-972.
32. Yang LL, Liang CY, Lu TC, Zhi CY, Liu B, Zhou JH, Liu XM, Gao HC, Huang W. Role of tissue transglutaminase and effect of cantharidinate in human colorectal cancer. Molecular Medicine Reports. 2013; 8:1812-1816.
33. Fernandez-Acenero MJ, Torres S, Garcia-Palmero I, Diaz Del Arco C, Casal JI. Prognostic role of tissue transglutaminase 2 in colon carcinoma. Virchows Archiv. 2016; 469:611-619.
34. Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, et al. Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer. Cancer Research. 2014; 74: 3238-47.
35. Cao LY, Petrusca DN, Satpathy M, Nakshatri H, Petrache I, Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis. 2008; 29:1893-1900.
36. Mehta K, Kumar A, Kim HI. Transglutaminase 2: A multitasking protein in the complex circuitry of inflammation and cancer. Biochemical Pharmacology. 2010; 80: 1921-1929.
37. Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K. Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells. Plos One. 2010; 5:e13390.
38. Fisher ML, Adhikary G, Xu W, Kerr C, Keillor JW, Eckert RL. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition. Oncotarget. 2015; 6:20525-20539. doi: 10.18632/oncotarget.3890.
39. Mehta K, Han A. Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. Cancers. 2011; 3:897-912.
40. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A. Targeting the TGFβ pathway for cancer therapy. Pharmacology & Therapeutics. 2015; 147: 22-31.
41. Olsen KC, Epa AP, Kulkarni AA, Kottmann RM, McCarthy CE, Johnson GV, Thatcher TH, Phipps RP, Sime PJ. Inhibition of Transglutaminase 2, a Novel Target for Pulmonary Fibrosis, by Two Small Electrophilic Molecules. American Journal of Respiratory Cell and Molecular Biology. 2014; 50:737-747.
42. Ranganathan P, Agrawal A, Bhushan R, Chavalmane AK, Kalathur RKR, Takahashi T, Kondaiah P. Expression profiling of genes regulated by TGF-beta: Differential regulation in normal and tumour cells. Bmc Genomics. 2007; 8:98.
43. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. Journal of the National Cancer Institute. 2000; 92: 1388-1402.
44. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275:1787-1790.
45. Condello S, Cao LY, Matei D. Tissue transglutaminase regulates beta-catenin signaling through a c-Src-dependent mechanism. Faseb Journal. 2013; 27:3100-3112.
46. Ilyas M, Tomlinson IPM, Rowan A, Pignatelli M, Bodmer WF. β-Catenin mutations in cell lines established from human colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94:10330-10334.
47. Myneni VD, Melino G, Kaartinen MT. Transglutaminase 2-a novel inhibitor of adipogenesis. Cell Death Dis. 2015; 6: e1868.
48. Faverman L, Mikhaylova L, Malmquist J, Nurminskaya M. Extracellular transglutaminase 2 activates betacatenin signaling in calcifying vascular smooth muscle cells. Febs Letters. 2008; 582: 1552-7. doi: 10.1016/j. febslet.2008.03.053
49. Chen SH, Chun YL, Lung TL, Geen DC, Ping Pl, Chin CH, Wen TK, Pei HT, Andrew VS, Jiuan JH, Ming TL. Up-regulation of Fibronectin and Tissue Transglutaminase Promotes Cell Invasion Involving Increased Association with Integrin and MMP Expression in A431 Cells. Anticancer Research. 2010; 30: 4177-4186.
50. Lee SH, Koo BS, Kim JM, Huang S, Rho YS, Bae WJ, Kang HJ, Kim YS, Moon JH, Lim YC. Wnt/β-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4. The Journal of pathology. 2014; 234:99-107.
51. Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K. Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. Plos One. 2011; 6:e20701.
52. Fang L, Zhu Q, Neuenschwander M, Specker E, Wulf-Goldenberg A, Weis WI, von Kries JP, Birchmeier W. A Small-Molecule Antagonist of the β-Catenin/TCF4 Interaction Blocks the Self-Renewal of Cancer Stem Cells and Suppresses Tumorigenesis. Cancer Research. 2016; 76: 891-901.
53. Wang Z, Perez M, Caja S, Melino G, Johnson TS, Lindfors K, Griffin M. A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell Death & Disease. 2013; 4:e808.
54. Wang Z, Collighan RJ, Pytel K, Rathbone DL, Li XL, Griffin M. Characterization of Heparin-binding Site of Tissue Transglutaminase its importance in cell surface targeting, matrix deposition, and cell signaling. Journal of Biological Chemistry. 2012; 287:13063-13083.
55. Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogenemediated transformation. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100:13567-13572.